March 20, 2019
Video
Mark D. Pegram, MD, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.
December 22, 2016
Video
Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses a phase II trial looking at ONT-380 in HER2+ breast cancer.
December 08, 2016
Video
Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses the phase III SOPHIA trial, which is exploring margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive breast cancer.
July 14, 2014
Video
Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.